Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCHW) Preferred Stock Liabilities (2022 - 2025)

Historic Preferred Stock Liabilities for Envoy Medical (COCHW) over the last 3 years, with Q3 2025 value amounting to $130000.0.

  • Envoy Medical's Preferred Stock Liabilities changed N/A to $130000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $130000.0, marking a year-over-year change of. This contributed to the annual value of $429.7 million for FY2022, which is N/A changed from last year.
  • Envoy Medical's Preferred Stock Liabilities amounted to $130000.0 in Q3 2025.
  • Envoy Medical's Preferred Stock Liabilities' 5-year high stood at $429.7 million during Q4 2022, with a 5-year trough of $130000.0 in Q3 2025.
  • Over the past 3 years, Envoy Medical's median Preferred Stock Liabilities value was $425.0 million (recorded in 2022), while the average stood at $256.5 million.
  • Data for Envoy Medical's Preferred Stock Liabilities shows a peak YoY increase of 8951.41% (in 2023) and a maximum YoY decrease of 8960.8% (in 2023) over the last 5 years.
  • Envoy Medical's Preferred Stock Liabilities (Quarter) stood at $429.7 million in 2022, then tumbled by 89.62% to $44.6 million in 2023, then plummeted by 99.71% to $130000.0 in 2025.
  • Its Preferred Stock Liabilities was $130000.0 in Q3 2025, compared to $44.6 million in Q2 2023 and $44.2 million in Q1 2023.